HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ GRANT SVCS

Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression - In Vivo Validation

Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression - In Vivo Validation is a funding opportunity from HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ GRANT SVCS, closing September 10, 2026.